IMTX

ImmaticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$18.00

+61.6% vs current

Most likely

Base case

60%

Probability

Target price

$12.00

+7.7% vs current

B-

Bear case

20%

Probability

Target price

$6.00

-46.1% vs current

AI sentiment snapshot

Latest data as of 2025-11-21

AI commentary

Market tone is cautious-to-constructive: investors are focused on upcoming data and cash runway disclosures, with selective interest around partnership potential [#IR] and sporadic news-driven spikes on program updates [#News]. Analysts and investors appear to price a binary clinical risk profile, leading to episodic volatility around announcements [#Clinical].

RankAlpha Sentiment AI - 2025-11-21

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

-eventNext quarterly financial report / SEC filingHigh impact

Quarterly results (revenue, cash burn) and management commentary that may shift near-term sentiment and cash runway assumptions [#IR].

-catalystPartnership / licensing announcementHigh impact

Potential strategic partnership or licensing deal that could provide non-dilutive capital or validation; lower-probability but high-impact if it occurs [#News].

-catalystClinical data readout for lead TCR-related programHigh impact

Potential efficacy/safety readout for a cell-therapy/TCR program that would materially de-risk the pipeline or, if negative, materially hurt valuation [#PR][#Clinical].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-11-21 • Updated nightlySource: Internal modelMethodology